What is Biorestorative Therapies Inc's earnings per share (EPS)?

Biorestorative Therapies Inc (BRTX) reported diluted earnings per share of $-1.58 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Biorestorative Therapies Inc Financials

BRTX

Source SEC Filings (10-K/10-Q) Updated Mar 26, 2026 Currency USD FYE March

This page shows Biorestorative Therapies Inc (BRTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 5/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Biorestorative Therapies Inc has an operating margin of -4350.1%, meaning the company retains $-4350 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -2881.6% the prior year.

Growth

Biorestorative Therapies Inc's revenue declined 10.3% year-over-year, from $401K to $360K. This contraction results in a growth score of 16/100.

Leverage

Biorestorative Therapies Inc has elevated debt relative to equity (D/E of 10.44), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Biorestorative Therapies Inc's current ratio of 0.84 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 12/100, which could limit financial flexibility.

Cash Flow

While Biorestorative Therapies Inc generated -$10.8M in operating cash flow, capex of $116K consumed most of it, leaving -$10.9M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Biorestorative Therapies Inc generates a -3992.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -105.3% the prior year.

Piotroski F-Score Weak

3/9

Biorestorative Therapies Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.76x

For every $1 of reported earnings, Biorestorative Therapies Inc generates $0.76 in operating cash flow (-$10.8M OCF vs -$14.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-58.8x

Biorestorative Therapies Inc earns $-58.8 in operating income for every $1 of interest expense (-$15.6M vs $266K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$360K

YoY-10.3%

5Y CAGR+36.1%

10Y CAGR-5.4%

Biorestorative Therapies Inc generated $360K in revenue in fiscal year 2025. This represents a decrease of 10.3% from the prior year.

EBITDA

-$15.4M

YoY-35.8%

Biorestorative Therapies Inc's EBITDA was -$15.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 35.8% from the prior year.

Net Income

-$14.2M

YoY-58.6%

Biorestorative Therapies Inc reported -$14.2M in net income in fiscal year 2025. This represents a decrease of 58.6% from the prior year.

EPS (Diluted)

$-1.58

Biorestorative Therapies Inc earned $-1.58 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 36.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$10.9M

YoY-30.8%

Biorestorative Therapies Inc generated -$10.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 30.8% from the prior year.

Cash & Debt

$1.5M

YoY+175.8%

5Y CAGR-13.2%

10Y CAGR+24.7%

Biorestorative Therapies Inc held $1.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

25M

Biorestorative Therapies Inc had 25M shares outstanding in fiscal year 2025. This represents an increase of 268.2% from the prior year.

Margins & Returns

Gross Margin

93.4%

YoY+0.4pp

10Y CAGR+34.9pp

Biorestorative Therapies Inc's gross margin was 93.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the prior year.

Operating Margin

-4350.1%

YoY-1468.5pp

5Y CAGR-775.9pp

10Y CAGR-3209.9pp

Biorestorative Therapies Inc's operating margin was -4350.1% in fiscal year 2025, reflecting core business profitability. This is down 1468.5 percentage points from the prior year.

Net Margin

-3959.4%

YoY-1720.2pp

5Y CAGR+10680.5pp

10Y CAGR-2699.5pp

Biorestorative Therapies Inc's net profit margin was -3959.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 1720.2 percentage points from the prior year.

Return on Equity

-3992.2%

YoY-3887.0pp

Biorestorative Therapies Inc's ROE was -3992.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 3887.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$10.1M

YoY+88.7%

5Y CAGR+63.0%

10Y CAGR+17.0%

Biorestorative Therapies Inc invested $10.1M in research and development in fiscal year 2025. This represents an increase of 88.7% from the prior year.

Share Buybacks

$2.0M

Biorestorative Therapies Inc spent $2.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$116K

YoY+9.3%

10Y CAGR-11.8%

Biorestorative Therapies Inc invested $116K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 9.3% from the prior year.

BRTX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$360K-10.3%	$401K+175.0%	$146K+21.7%	$120K+160.4%	$46K-40.3%	$77K
Cost of Revenue	$24K-15.1%	$28K	N/A	N/A	N/A	N/A
Gross Profit	$336K-9.9%	$373K+155.8%	$146K	N/A	N/A	N/A
R&D Expenses	$10.1M+88.7%	$5.3M+32.6%	$4.0M+14.8%	$3.5M+381.9%	$729K-16.9%	$877K
SG&A Expenses	$5.9M-10.5%	$6.6M-41.9%	$11.3M-27.3%	$15.6M-39.2%	$25.6M+1334.2%	$1.8M
Operating Income	-$15.6M-35.4%	-$11.6M+24.1%	-$15.2M+19.8%	-$19.0M+27.9%	-$26.3M-855.9%	-$2.8M
Interest Expense	$266K-56.8%	$616K+11.5%	$552K+4640.7%	$12K+100.6%	-$1.8M	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$14.2M-58.6%	-$9.0M+13.8%	-$10.4M+21.2%	-$13.2M+70.2%	-$44.3M-293.0%	-$11.3M
EPS (Diluted)	$-1.58	$-1.16+53.0%	$-2.47+32.3%	$-3.65	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$12K-96.1%	$303K+1113.2%	$25K-42.3%	$43K-81.5%	$234K+162.2%	$89K+154.6%	$35K+81.3%	$19K
Cost of Revenue	$11K+21.1%	$9K+200.1%	$3K	N/A	$18K+181.1%	$6K	N/A	N/A
Gross Profit	$1K-99.6%	$295K+1233.4%	$22K-44.7%	$40K-81.4%	$215K+160.7%	$83K+136.0%	$35K	N/A
R&D Expenses	$2.6M+16.6%	$2.2M+29.8%	$1.7M+23.9%	$1.4M-4.8%	$1.5M0.0%	$1.5M+37.4%	$1.1M-2.9%	$1.1M
SG&A Expenses	$1.1M-18.8%	$1.4M-55.9%	$3.1M+131.3%	$1.3M+28.4%	$1.0M-4.4%	$1.1M-64.4%	$3.1M+43.6%	$2.1M
Operating Income	-$3.7M-12.2%	-$3.3M+31.2%	-$4.8M-78.7%	-$2.7M-17.6%	-$2.3M+7.4%	-$2.5M+39.9%	-$4.1M-27.6%	-$3.2M
Interest Expense	$58K-21.9%	$74K-26.1%	$100K-16.0%	$119K-25.0%	$159K-9.9%	$176K+8.2%	$163K-56.8%	$376K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.0M-14.4%	-$2.7M+50.3%	-$5.3M-226.4%	-$1.6M-49.9%	-$1.1M+72.9%	-$4.0M-81.2%	-$2.2M+3.5%	-$2.3M
EPS (Diluted)	$-0.33-10.0%	$-0.30+53.1%	$-0.64	N/A	$-0.13+74.0%	$-0.50-51.5%	$-0.33	N/A

BRTX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$4.1M-66.8%	$12.3M-2.6%	$12.6M-23.3%	$16.4M-26.8%	$22.5M+416.5%	$4.3M
Current Assets	$3.1M-71.9%	$11.1M-2.2%	$11.4M-24.7%	$15.1M-29.5%	$21.5M+573.6%	$3.2M
Cash & Equivalents	$1.5M+175.8%	$548K-38.0%	$884K-48.4%	$1.7M-91.8%	$21.0M+586.1%	$3.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$16K-91.8%	$188K+876.2%	$19K+20.6%	$16K+220.0%	$5K-70.6%	$17K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.7M-0.7%	$3.7M+43.8%	$2.6M-57.6%	$6.1M-47.4%	$11.7M+105.5%	$5.7M
Current Liabilities	$3.7M-0.7%	$3.7M+43.8%	$2.6M-56.4%	$6.0M+1544.2%	$364K-65.2%	$1.0M
Long-Term Debt	N/A	N/A	N/A	N/A	$250K	N/A
Total Equity	$357K-95.8%	$8.5M-14.7%	$10.0M-2.8%	$10.3M-4.6%	$10.8M+909.8%	-$1.3M
Retained Earnings	-$169.9M-9.1%	-$155.7M-6.1%	-$146.7M-7.6%	-$136.3M-1.6%	-$134.1M-49.3%	-$89.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$5.6M-33.7%	$8.5M-17.5%	$10.3M-15.9%	$12.3M-15.7%	$14.6M-9.6%	$16.1M-10.2%	$18.0M+42.3%	$12.6M
Current Assets	$4.7M-38.0%	$7.6M-18.8%	$9.4M-16.1%	$11.1M-17.5%	$13.5M-10.0%	$15.0M-10.5%	$16.8M+47.2%	$11.4M
Cash & Equivalents	$602K-61.3%	$1.6M+26.6%	$1.2M+124.3%	$548K-63.2%	$1.5M-33.9%	$2.3M+94.6%	$1.2M+30.8%	$884K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$13K-10.7%	$15K-40.0%	$25K-86.7%	$188K+14.2%	$165K+502.2%	$27K-21.7%	$35K+81.3%	$19K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.4M-6.4%	$3.7M-12.2%	$4.2M+11.6%	$3.7M-18.2%	$4.6M-13.9%	$5.3M+54.3%	$3.4M+32.2%	$2.6M
Current Liabilities	$3.4M-6.4%	$3.7M-12.2%	$4.2M+11.6%	$3.7M-18.2%	$4.6M-13.9%	$5.3M+54.3%	$3.4M+32.2%	$2.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.2M-54.5%	$4.8M-21.1%	$6.1M-28.0%	$8.5M-14.6%	$10.0M-7.5%	$10.8M-25.5%	$14.5M+45.0%	$10.0M
Retained Earnings	-$166.7M-1.9%	-$163.7M-1.6%	-$161.0M-3.4%	-$155.7M-1.1%	-$154.0M-0.7%	-$153.0M-2.7%	-$148.9M-1.5%	-$146.7M

BRTX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$10.8M-31.1%	-$8.2M-28.0%	-$6.4M-8.7%	-$5.9M-77.6%	-$3.3M-69.5%	-$2.0M
Capital Expenditures	$116K+9.3%	$106K-37.9%	$171K-35.5%	$265K+765.1%	$31K	N/A
Free Cash Flow	-$10.9M-30.8%	-$8.3M-26.3%	-$6.6M-6.8%	-$6.2M-83.8%	-$3.4M	N/A
Investing Cash Flow	$8.9M+1629.2%	$515K-84.2%	$3.3M+124.3%	-$13.4M-43607.5%	-$31K	N/A
Financing Cash Flow	$2.9M-61.3%	$7.4M+214.2%	$2.3M	N/A	$21.3M+324.1%	$5.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$2.0M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$2.9M-7.7%	-$2.7M+3.1%	-$2.8M-18.4%	-$2.3M-38.1%	-$1.7M+8.9%	-$1.9M+19.5%	-$2.3M-46.0%	-$1.6M
Capital Expenditures	$0	$0-100.0%	$36K+192.7%	$12K-78.7%	$58K	N/A	N/A	$70K
Free Cash Flow	-$2.9M-7.7%	-$2.7M+4.3%	-$2.8M-19.3%	-$2.4M-34.3%	-$1.8M	N/A	N/A	-$1.7M
Investing Cash Flow	$2.0M-6.3%	$2.1M-9.9%	$2.4M+54.4%	$1.5M+63.6%	$937K-68.5%	$3.0M+160.3%	-$4.9M-5711.5%	-$85K
Financing Cash Flow	-$49K-105.6%	$888K-18.7%	$1.1M+965.1%	-$126K	$0+100.0%	-$13K-100.2%	$7.5M+8950.5%	$83K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BRTX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	93.4%+0.4pp	93.0%-7.0pp	100.0%	N/A	N/A	N/A
Operating Margin	-4350.1%-1468.5pp	-2881.6%+7557.9pp	-10439.5%+5398.6pp	-15838.1%+41352.9pp	-57191.0%-53616.9pp	-3574.1%
Net Margin	-3959.4%-1720.2pp	-2239.3%+4905.9pp	-7145.2%+3891.8pp	-11037.0%+85274.5pp	-96311.5%-81671.7pp	-14639.9%
Return on Equity	-3992.2%-3887.0pp	-105.3%-1.1pp	-104.1%+24.4pp	-128.5%+282.4pp	-410.9%	N/A
Return on Assets	-349.1%-276.0pp	-73.1%+9.5pp	-82.6%-2.1pp	-80.5%+116.9pp	-197.3%+62.0pp	-259.3%
Current Ratio	0.84-2.1	2.97-1.4	4.37+1.8	2.53-56.5	59.01+56.0	3.05
Debt-to-Equity	10.44+10.0	0.44+0.2	0.26-0.3	0.60+0.6	0.02+4.3	-4.26
FCF Margin	-3031.7%-952.8pp	-2078.9%+2448.7pp	-4527.6%+629.6pp	-5157.2%+2148.4pp	-7305.6%	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	10.4%-86.7pp	97.1%+8.8pp	88.4%-3.9pp	92.3%+0.1pp	92.2%-0.5pp	92.7%-7.3pp	100.0%	N/A
Operating Margin	-31432.3%-30342.5pp	-1089.8%+18140.4pp	-19230.1%-13017.3pp	-6212.8%-5233.8pp	-979.0%+1791.8pp	-2770.8%+8969.9pp	-11740.7%+4946.7pp	-16687.5%
Net Margin	-25748.1%-24872.3pp	-875.8%+20483.4pp	-21359.2%-17580.6pp	-3778.6%-3311.4pp	-467.2%+4054.2pp	-4521.4%+1830.8pp	-6352.2%+5585.6pp	-11937.8%
Return on Equity	-137.7%-82.8pp	-54.8%+32.1pp	-86.9%-67.7pp	-19.2%-8.3pp	-10.9%+26.4pp	-37.3%-22.0pp	-15.3%+7.7pp	-23.0%
Return on Assets	-53.8%-22.6pp	-31.2%+20.5pp	-51.7%-38.4pp	-13.3%-5.8pp	-7.5%+17.5pp	-25.0%-12.6pp	-12.4%+5.9pp	-18.3%
Current Ratio	1.37-0.7	2.07-0.2	2.24-0.7	2.97+0.0	2.95+0.1	2.82-2.0	4.86+0.5	4.37
Debt-to-Equity	1.56+0.8	0.76+0.1	0.68+0.2	0.44-0.0	0.46-0.0	0.49+0.3	0.24-0.0	0.26
FCF Margin	-24585.9%-23697.7pp	-888.2%+10372.5pp	-11260.7%-5809.8pp	-5451.0%-4698.4pp	-752.6%	N/A	N/A	-8590.6%

Note: The current ratio is below 1.0 (0.84), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Aptorum Group Ltd APM

$7.8M

Xtl Biopharmaceu XTLB

$5.8M

Briacell Therapeutics Corp BCTX

$30.0M

Biovie Inc BIVI

$10.4M

Biomx Inc PHGE

$21.6M

Frequently Asked Questions

What is Biorestorative Therapies Inc's annual revenue?

Biorestorative Therapies Inc (BRTX) reported $360K in total revenue for fiscal year 2025. This represents a -10.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Biorestorative Therapies Inc's revenue growing?

Biorestorative Therapies Inc (BRTX) revenue declined by 10.3% year-over-year, from $401K to $360K in fiscal year 2025.

Is Biorestorative Therapies Inc profitable?

No, Biorestorative Therapies Inc (BRTX) reported a net income of -$14.2M in fiscal year 2025, with a net profit margin of -3959.4%.

What is Biorestorative Therapies Inc's EBITDA?

Biorestorative Therapies Inc (BRTX) had EBITDA of -$15.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Biorestorative Therapies Inc's gross margin?

Biorestorative Therapies Inc (BRTX) had a gross margin of 93.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Biorestorative Therapies Inc's operating margin?

Biorestorative Therapies Inc (BRTX) had an operating margin of -4350.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Biorestorative Therapies Inc's net profit margin?

Biorestorative Therapies Inc (BRTX) had a net profit margin of -3959.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Biorestorative Therapies Inc's return on equity (ROE)?

Biorestorative Therapies Inc (BRTX) has a return on equity of -3992.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Biorestorative Therapies Inc's free cash flow?

Biorestorative Therapies Inc (BRTX) generated -$10.9M in free cash flow during fiscal year 2025. This represents a -30.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Biorestorative Therapies Inc's operating cash flow?

Biorestorative Therapies Inc (BRTX) generated -$10.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Biorestorative Therapies Inc's total assets?

Biorestorative Therapies Inc (BRTX) had $4.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Biorestorative Therapies Inc's capital expenditures?

Biorestorative Therapies Inc (BRTX) invested $116K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Biorestorative Therapies Inc spend on research and development?

Biorestorative Therapies Inc (BRTX) invested $10.1M in research and development during fiscal year 2025.

Does Biorestorative Therapies Inc buy back shares?

Yes, Biorestorative Therapies Inc (BRTX) spent $2.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Biorestorative Therapies Inc have outstanding?

Biorestorative Therapies Inc (BRTX) had 25M shares outstanding as of fiscal year 2025.

What is Biorestorative Therapies Inc's current ratio?

Biorestorative Therapies Inc (BRTX) had a current ratio of 0.84 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Biorestorative Therapies Inc's debt-to-equity ratio?

Biorestorative Therapies Inc (BRTX) had a debt-to-equity ratio of 10.44 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Biorestorative Therapies Inc's return on assets (ROA)?

Biorestorative Therapies Inc (BRTX) had a return on assets of -349.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Biorestorative Therapies Inc's cash runway?

Based on fiscal year 2025 data, Biorestorative Therapies Inc (BRTX) had $1.5M in cash against an annual operating cash burn of $10.8M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Biorestorative Therapies Inc's Piotroski F-Score?

Biorestorative Therapies Inc (BRTX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Biorestorative Therapies Inc's earnings high quality?

Biorestorative Therapies Inc (BRTX) has an earnings quality ratio of 0.76x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Biorestorative Therapies Inc cover its interest payments?

Biorestorative Therapies Inc (BRTX) has an interest coverage ratio of -58.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Biorestorative Therapies Inc?

Biorestorative Therapies Inc (BRTX) scores 5 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.